John J. Kirby

Insider · Interim CFO · VRCA

John J. Kirby files insider transactions with the SEC as an interim cfo of Verrica Pharmaceuticals (VRCA). We hold 1 disclosed purchase or sale filed since 22 August 2012, 1 of them in the last 90 days.

Files forVRCA
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure18 August 2026

Positions held

4 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 6 November 2024 — 18 August 2026Interim CFO · Verrica Pharmaceuticals (VRCA)5 Form 4 lines · source: SEC Form 4
Filed 20 January 2023 — 20 January 2023Chief Financial Officer · Aceragen (ACGN)1 Form 4 line · source: SEC Form 4
Filed 3 January 2019 — 6 January 2023Chief Financial Officer · Idera Pharmaceuticals (IDRA)19 Form 4 lines · source: SEC Form 4
Filed 20 August 2012 — 24 January 2014V.P., Chief Accounting Officer · Viropharma (VPHM)9 Form 4 lines · source: SEC Form 4

Everything they disclosed

34 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 5,000 shares of Verrica PharmaceuticalsSEC Form 418 August 2026Common Stock · traded 18 August 2026 · filed 18 August 2026
was granted 10,000 shares of Verrica PharmaceuticalsSEC Form 430 December 2025Common Stock · traded 23 December 2025 · filed 30 December 2025
▲ bought on the open market 884 shares of Verrica Pharmaceuticals (a derivative holding)SEC Form 425 November 2025Series C Warrant (right to buy) · traded 25 November 2025 · filed 25 November 2025
▲ bought on the open market 3,536 shares of Verrica PharmaceuticalsSEC Form 425 November 2025Common Stock · traded 25 November 2025 · filed 25 November 2025
was granted 54,267 shares of Verrica PharmaceuticalsSEC Form 46 November 2024Common Stock · traded 6 November 2024 · filed 6 November 2024
was granted 25,400 shares of Aceragen (a derivative holding)SEC Form 42 February 2023Stock Options (Right to Buy) · traded 20 January 2023 · filed 2 February 2023
was granted 399,218 shares of Idera PharmaceuticalsSEC Form 410 January 2023Common Stock · traded 6 January 2023 · filed 10 January 2023
had shares withheld for tax on 119,957 shares of Idera PharmaceuticalsSEC Form 410 January 2023Common Stock · traded 6 January 2023 · filed 10 January 2023
was granted 66,500 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 47 July 2022Stock Option (Right to Buy) · traded 6 July 2022 · filed 7 July 2022
was granted 41,500 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 44 April 2022Stock Option (Right to Buy) · traded 1 April 2022 · filed 4 April 2022
was granted 25,000 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 426 January 2022Stock Option (Right to Buy) · traded 24 January 2022 · filed 26 January 2022
▲ bought on the open market 10,000 shares of Idera PharmaceuticalsSEC Form 421 December 2021Common Stock · traded 17 December 2021 · filed 21 December 2021
was granted 66,500 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 412 July 2021Stock Option (Right to Buy) · traded 8 July 2021 · filed 12 July 2021
▼ sold on the open market 6,250 shares of Idera PharmaceuticalsSEC Form 429 March 2021Common Stock · traded 25 March 2021 · filed 29 March 2021
▼ sold on the open market 1,693 shares of Idera PharmaceuticalsSEC Form 412 January 2021Common Stock · traded 12 January 2021 · filed 12 January 2021
was granted 51,000 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 412 January 2021Stock Option (Right to Buy) · traded 8 January 2021 · filed 12 January 2021
▼ sold on the open market 862 shares of Idera PharmaceuticalsSEC Form 46 January 2021Common Stock · traded 5 January 2021 · filed 6 January 2021
was granted 50,000 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 423 July 2020Stock Option (Right to Buy) · traded 21 July 2020 · filed 23 July 2020
▼ sold on the open market 911 shares of Idera PharmaceuticalsSEC Form 414 January 2020Common Stock · traded 7 January 2020 · filed 14 January 2020
was granted 50,000 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 414 January 2020Stock Option (Right to Buy) · traded 10 January 2020 · filed 14 January 2020
was granted 20,000 shares of Idera PharmaceuticalsSEC Form 414 January 2020Common Stock · traded 10 January 2020 · filed 14 January 2020
▼ sold on the open market 911 shares of Idera PharmaceuticalsSEC Form 410 January 2020Common Stock · traded 7 January 2020 · filed 10 January 2020
was granted 45,500 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 411 July 2019Stock Option (Right to Buy) · traded 9 July 2019 · filed 11 July 2019
was granted 25,600 shares of Idera Pharmaceuticals (a derivative holding)SEC Form 47 January 2019Stock Option (Right to Buy) · traded 3 January 2019 · filed 7 January 2019
was granted 10,250 shares of Idera PharmaceuticalsSEC Form 47 January 2019Common Stock · traded 3 January 2019 · filed 7 January 2019
disposed of in a tender offer 60 shares of ViropharmaSEC Form 428 January 2014Common Stock · traded 24 January 2014 · filed 28 January 2014
was granted 1,980 shares of ViropharmaSEC Form 428 January 2014Common Stock · traded 24 January 2014 · filed 28 January 2014
returned to the issuer 1,980 shares of ViropharmaSEC Form 428 January 2014Common Stock · traded 24 January 2014 · filed 28 January 2014
returned to the issuer 15,000 shares of Viropharma (a derivative holding)SEC Form 428 January 2014Employee Stock Option (Right to Buy) · traded 24 January 2014 · filed 28 January 2014
returned to the issuer 3,960 shares of Viropharma (a derivative holding)SEC Form 428 January 2014Employee Stock Option (Right to Buy) · traded 24 January 2014 · filed 28 January 2014
returned to the issuer 6,000 shares of Viropharma (a derivative holding)SEC Form 428 January 2014Employee Stock Option (Right to Buy) · traded 24 January 2014 · filed 28 January 2014
was granted 6,000 shares of Viropharma (a derivative holding)SEC Form 412 June 2013Employee Stock Option (Right to Buy) · traded 10 June 2013 · filed 12 June 2013
was granted 3,960 shares of Viropharma (a derivative holding)SEC Form 47 January 2013Employee Stock Option (Right to Buy) · traded 3 January 2013 · filed 7 January 2013
was granted 15,000 shares of Viropharma (a derivative holding)SEC Form 422 August 2012Employee Stock Option (Right to Buy) · traded 20 August 2012 · filed 22 August 2012

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.